Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists
A. Nitta(Toray (United States)), Toshiya Takahashi(Tohoku University), Makoto Takeuchi(Osaka International Cancer Institute), Hirokazu Kubota(Astellas Pharma (Japan)), Koichiro Morihira(Astellas Pharma (Japan)), Mitsuaki Ohta(Tokyo University of Agriculture), Ippei Sato(Astellas Pharma (Japan)), Tatsuaki Morokata(Astellas Pharma (Japan)), Hideki Inoue(Kumamoto City Hospital), Shin‐ichi Tsukamoto(Astellas Pharma (Japan)), Takayuki Imaoka(Toray Industries, Inc. (Japan)), Yosuke Iura(Toray (United States))
Cited by 6
Related Papers
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
|Arthritis & Rheumatology|2016|119
Psoriasis and Antimicrobial Peptides
|International Journal of Molecular Sciences|2020|114
Poor prognosis in esophageal cancer patients with postoperative complications
|Surgery Today|1998|96
An In Vitro Test to Screen Skin Sensitizers Using a Stable THP-1–Derived IL-8 Reporter Cell Line, THP-G8
|Toxicological Sciences|2011|93
Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors
|Scientific Reports|2018|84